Lianying Healthcare (688271): Overseas business is growing rapidly, and domestic business is expected to reach an inflection point
Research reports on investment opportunities丨Fangzheng Securities: United Imaging Healthcare is expected to continue strong growth and is given an initial 'recommended' rating.
Lianying Healthcare (688271): Leading innovation in intelligent medical imaging in large countries drives global breakthroughs
Lianying Healthcare (688271): Overseas expansion accelerates and revenue recovery can be expected in the fourth quarter
UNITED IMAGING(688271):ANTICIPATING A RAPID REBOUND IN DOMESTIC BUSINESS
Lianying Healthcare (688271): Short-term performance is under pressure to maintain high overseas growth
Lianying Healthcare (688271): Outstanding overseas performance, optimistic about subsequent domestic recovery
Lianying Healthcare (688271): A pioneer in domestic medical imaging equipment, leading the way in global development
Lianying Healthcare (688271): Short-term performance is expected to gradually improve in the second half of the year due to policy disturbances
Lianying Healthcare (688271): Steady growth in business performance, impressive overseas business performance
UNITED IMAGING(688271):RESILIENT 1H24 PERFORMANCE AMID MARKET HEADWINDS
Nomura Adjusts Shanghai United Imaging Healthcare's Price Target to 110.40 Yuan From 122.36 Yuan, Keeps at Neutral
Lianying Healthcare (688271): Improving the fundamentals of 1H24 under pressure requires attention to the pace of recruitment and recovery
Lianying Healthcare (688271): Favorable policies are expected to release demand in the imaging market
Lianying Healthcare (688271): High-end products lead growth and outstanding overseas performance
Lianying Healthcare (688271): Investing in Jiuyiyuan Nuclear Medicine Comprehensive Diagnosis and Treatment Capability Enhancement
Research Reports | CICC: United Imaging Acquires Jiuyi Yuan, Enhancing the Overall Competitiveness of the Medical Imaging Sector
Lianying Healthcare (688271): Acquisition of Jiuyiyuan strengthens the overall competitiveness of the molecular imaging sector
Nomura Adjusts Shanghai United Imaging Healthcare's Price Target to 122.36 Yuan From 139.25 Yuan, Keeps at Neutral
Major bank rating: CMB International: bullish on innovative drugs and leading medical device companies with high growth in medical consumer stocks due to attractive valuations in the pharmaceutical industry.